These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21667439)

  • 1. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia.
    Kaji H; Imanishi Y; Sugimoto T; Seino S
    Exp Clin Endocrinol Diabetes; 2011 Jul; 119(7):440-4. PubMed ID: 21667439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sclerostin and DKK1 in primary hyperparathyroidism.
    Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
    Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study.
    Ardawi MS; Rouzi AA; Al-Sibiani SA; Al-Senani NS; Qari MH; Mousa SA
    J Bone Miner Res; 2012 Dec; 27(12):2592-602. PubMed ID: 22836717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
    Xu XJ; Shen L; Yang YP; Lu FR; Zhu R; Shuai B; Li CG; Wu MX
    Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum sclerostin levels and metabolic bone diseases].
    Yamauchi M; Sugimoto T
    Clin Calcium; 2013 Jun; 23(6):877-83. PubMed ID: 23719501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Increase of PTH in post-menopausal osteoporosis].
    Cerdà D; Peris P; Monegal A; Albaladejo C; Martínez de Osaba MJ; Surís X; Guañabens N
    Rev Clin Esp; 2011; 211(7):338-43. PubMed ID: 21596374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.
    van Lierop AH; Witteveen JE; Hamdy NA; Papapoulos SE
    Eur J Endocrinol; 2010 Nov; 163(5):833-7. PubMed ID: 20817762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.
    Gatti D; Viapiana O; Adami S; Idolazzi L; Fracassi E; Rossini M
    Bone; 2012 Mar; 50(3):739-42. PubMed ID: 22178539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
    J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women.
    Drake MT; Srinivasan B; Mödder UI; Peterson JM; McCready LK; Riggs BL; Dwyer D; Stolina M; Kostenuik P; Khosla S
    J Clin Endocrinol Metab; 2010 Nov; 95(11):5056-62. PubMed ID: 20631014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.
    Reppe S; Noer A; Grimholt RM; Halldórsson BV; Medina-Gomez C; Gautvik VT; Olstad OK; Berg JP; Datta H; Estrada K; Hofman A; Uitterlinden AG; Rivadeneira F; Lyle R; Collas P; Gautvik KM
    J Bone Miner Res; 2015 Feb; 30(2):249-56. PubMed ID: 25155887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.
    Piemonte S; Romagnoli E; Bratengeier C; Woloszczuk W; Tancredi A; Pepe J; Cipriani C; Minisola S
    J Endocrinol Invest; 2012 Oct; 35(9):866-8. PubMed ID: 22842667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study.
    Garnero P; Sornay-Rendu E; Munoz F; Borel O; Chapurlat RD
    Osteoporos Int; 2013 Feb; 24(2):489-94. PubMed ID: 22525978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
    J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of serum sclerostin in healthy pre- and postmenopausal women.
    Ardawi MS; Al-Kadi HA; Rouzi AA; Qari MH
    J Bone Miner Res; 2011 Dec; 26(12):2812-22. PubMed ID: 21812027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative normal level of parathyroid hormone signifies an early and mild form of primary hyperparathyroidism.
    Bergenfelz A; Lindblom P; Lindergård B; Valdemarsson S; Westerdahl J
    World J Surg; 2003 Apr; 27(4):481-5. PubMed ID: 12658497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
    Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes.
    Ardawi MS; Akhbar DH; Alshaikh A; Ahmed MM; Qari MH; Rouzi AA; Ali AY; Abdulrafee AA; Saeda MY
    Bone; 2013 Oct; 56(2):355-62. PubMed ID: 23845326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.